Footnotes

• Twitter @biomedsimlab

• Contributors Both authors contributed equally to the writing of this column.

• Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

• Competing interests MJG - Has been a consultant on a fee-per-hour basis for Astrocyte Pharmaceuticals, Cerenovus, Imperative Care, Medtronic Neurovascular, Mivi Neurosciences, Phenox, Q’Apel, Route 92 Medical, Stryker Neurovascular, and Wallaby Medical; holds stock in Galaxy Medical, Imperative Care, InNeuroCo and Neurogami; and has received research support from National Institutes of Health (NIH), the United States–Israel Binational Science Foundation, Anaconda, ApicBio, Arsenal Medical, Axovant, Cerenovus, Ceretrieve, Cook Medical, Galaxy Therapeutics, Gentuity, Imperative Care, InNeuroCo, Insera, Magneto, Microvention, Medtronic Neurovascular, MIVI Neurosciences, Naglreiter MDDO, Neurogami, Omniox, Philips Healthcare, Rapid Medical, Route 92 Medical, Stryker Neurovascular, Syntheon, ThrombX Medical and the Wyss Institute. DAS - None declared.

• Provenance and peer review Commissioned; internally peer reviewed.